INC Research Holdings, Inc. (NYSE:INCR)‘s stock had its “outperform” rating reissued by equities research analysts at Credit Suisse Group in a note issued to investors on Tuesday. They currently have a $54.00 target price on the stock, down from their previous target price of $68.00.
COPYRIGHT VIOLATION WARNING: “Credit Suisse Group Reiterates Outperform Rating for INC Research Holdings, Inc. (INCR)” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/14/credit-suisse-group-reiterates-outperform-rating-for-inc-research-holdings-inc-incr.html.
About INC Research Holdings
INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.